Evidence supporting the use of: Acetyl L-carnitine
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Acetyl L-carnitine (ALC) has some scientific support for its use in Multiple Sclerosis (MS), primarily for the management of fatigue, which is a common and debilitating symptom in MS patients. The rationale for its use is based on its role in mitochondrial energy metabolism and its potential neuroprotective effects. Several small, randomized controlled trials and open-label studies have investigated ALC in this context. Notably, a 2004 randomized controlled trial published in Neurology found that ALC was as effective as amantadine (a standard treatment for MS-related fatigue) in reducing fatigue severity, with fewer side effects. Other studies have shown similar benefits, suggesting modest improvements in fatigue scores compared to placebo. However, most studies are limited by small sample sizes and short duration, and there is a lack of large, long-term trials.

There is no strong evidence that ALC modifies the underlying disease process of MS or impacts relapse rate or disability progression. Its use is therefore adjunctive and symptom-focused. Guidelines from some neurological societies suggest ALC can be considered when first-line therapies for MS-related fatigue are ineffective or not tolerated. Overall, while scientific evidence is modest and not definitive, it does justify consideration of ALC in managing MS-related fatigue, warranting a rating of 2/5 for evidence strength.

More about Acetyl L-carnitine
More about Multiple Sclerosis